Follow us on Twitter
twitter icon@FreshPatents


Infectious patents

      

This page is updated frequently with new Infectious-related patent applications.

SALE: 260+ Infectious-related patent PDFs



 Light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging patent thumbnailLight-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging
The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a mycobacterium tuberculosis (m.
The John Hopkins University


 Activation of adaptive immune processes for the treatment of cancers and infectious diseases patent thumbnailActivation of adaptive immune processes for the treatment of cancers and infectious diseases
Polypeptides, such as a multi-valent polypeptide designated svd2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. Svd2 demonstrated in vivo activity in a syngeneic mouse model.
Susavion Biosciences, Inc.


 Pyrazolopyrimidine compounds patent thumbnailPyrazolopyrimidine compounds
Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

 Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning patent thumbnailDistinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning
Discloses are a method for detecting norovirus using a norovirus animal model, a method for screening an antivial agent against norovirus, and a composition for neutralizing the infection with an enteric virus, containing concanavalin a as an active ingredient, so that the method for detecting norovirus can allow the distinction between infectious norovirus and non-infectious norovirus, and the composition can neutralize a virus causing food poisoning.. .
Korea Basic Science Institute


 Method for rapidly determining effective sterilization , deimmunization, and/or disinfection patent thumbnailMethod for rapidly determining effective sterilization , deimmunization, and/or disinfection
A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device.
Oneightyºc Technologies Corporation


 Immunomodulators patent thumbnailImmunomodulators
The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company


 Immunomodulators patent thumbnailImmunomodulators
The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company


 Macrocyclic compounds as trk kinase inhibitors patent thumbnailMacrocyclic compounds as trk kinase inhibitors
Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.


 Antibodies to tigit patent thumbnailAntibodies to tigit
The invention provides monoclonal antibodies that specifically bind to tigit. The monoclonal antibodies have the capacity for substantial activation of t cells and natural killer cells by inhibiting binding of tigit to cd155.
Abmuno Therapeutics Llc


 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease patent thumbnailPooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
The invention relates to the field of cell therapy, particularly nk cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (nk cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled nk cells from umbilical cord blood units (ucbs), preferably alloreactive nk cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (adcc) mechanism.
Emercell Sas


Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Method for analyzing health signal to respond to infectious disease and apparatus thereof

A method and an apparatus for analyzing a biosignal to respond to an infectious disease are provided. An analyzing method involves receiving biosignals of users of terminals and location information of the terminals, determining infectiousness of a condition of a user among the users by analyzing the location information and the biosignals, and transmitting feedback information regarding the infectiousness of the condition to one or more of the terminals..
Samsung Electronics Co., Ltd.

Production pluripotent stem cells having antigen-specific t cell receptor gene

(2) inducing t cell progenitors or mature t cells from the pluripotent stem cells provided in step (1). Pluripotent stem cells may preferably be ips cells.

Methionine analogs and methods of using same

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Pharmaceutical formulations that form gel in situ

The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a ph regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject..
Iview Therapeutics, Inc.

A novel synergistic herbal formulation for degenerative disease cardiovascular diseases, autoimmune, inflammatory and metabolism disorder and the process of preparing the same

The present invention relates to a novel synergistic herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases and metabolism disorder etc. Of man, animal and plants more particularly, the present invention relates to the herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases etc which is prepared by using preparation of pongamia pinnata, dalbergia sissoo (shishu) and syzygium aromaticum (clove) which is used as directly and neuro pathways.

Prevention and treatment of microbial infections

Compositions for prevention and treatment of microbial infectious, such as microbial infections that comprise a biofilm, or a microbe that is capable of forming a biofilm are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substance that includes a substrate for the enzyme.
Matoke Holdings Limited

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum.
Sapporo Medical University

Drug delivery system and treating ocular diseases in animals

The present invention relates in general to the field of drug delivery systems for treating ocular diseases in animals, and more specifically, to a drug delivery system and method of treating infectious bovine keratoconjunctivitis (“ibk”) in cattle, commonly known as “pinkeye.” the drug delivery system and method may include a contact lens that has been infused with drugs for treating ibk, such as oxytetracycline, penicillin, streptomycin, tetracycline, gentamicin, cloxacillin or combinations thereof. The medicated contact lens may be placed in contact with the cornea and/or conjunctiva of the afflicted eye of the animal.

Methods and rapid detection of infectious microorganisms

An array of micro-chambers (220) with isfets (300) disposed therein for monitoring single cell activity in the microarray to determine the presence or absence of microorganisms in a sample (390).. .
Becton, Dickinson And Company

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Thienopyrroles as histone demethylase inhibitors

The present application relates to thienopyrrole derivatives, compounds of formulas (i) and (ia), wherein r, r1, r2 and r3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting kdm1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity..
Istituto Europeo Di Oncologia S.r.l.

Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Presently provided are inhibitors of ido and tdo and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.. .
Newlink Genetics Corporation

Emulsified vaccine to obtain formulations of concentrated igy immunoglobulins; processes and uses for the same

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.. .
Investiacion Aplicada, S.a. De C.v.

Protective covering for preexisting affixed medical equipment safety straps

A disposable cover used to protect preexisting affixed safety straps on medical equipment. The cover includes: 2 protective panels and hoop and loop fasteners on the inside for securing the cover to the preexisting affixed strap and hook and loop fasteners on the outer surface to allow the cover to secure to the opposing cover.

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Immunomodulators

The present disclosure provides novel macrocyclic compounds which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Organic vaccination an alternative method to traditional preventative vaccination

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive t and b lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject.

Protein-chaperoned t-cell vaccines

Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone.
Massachusetts Institute Of Technology

Devices and methods for using endovascular cooling to treat septic shock and other disorders

Apparatus, systems and methods for cooling or warming the temperature of all or a portion of the body of a human or animal subject to treat disorders including but not limited to sepsis, septic shock or other inflammatory or infectious conditions which can result in shock, hypoxia, ischemia and/or multiple organ failure in human or animal subjects.. .
Zoll Circulation, Inc.

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
President And Fellows Of Harvard College

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Infectious hepatitis c viruses of genotype 3a and 4a and uses thereof

The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis c virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis c viruses of either genotype 3a (strain s52) or genotype 4a (strain ed43).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Anti-tim-3 antibodies

Anti-tim-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or t-cell dysfunctional disorders. Bispecific antibodies against tim-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against tim-3 and cd3..
Agency For Science, Technology And Research

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof.
Regeneron Pharmaceuticals, Inc.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Compositions for the treatment of peritonitis

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.. .
Reponex Pharmaceuticals Aps

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity.. .
Mabquest Sa

Gm-csf and il-4 conjugates, compositions, and methods related thereto

In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of gm-csf and a polypeptide il-4. Typically, the gm-csf and il-4 are connected by a linker, e.g., polypeptide.
Children's Healthcare Of Atlanta, Inc.

Fluorinated benzofuranyl-pyrimidine derivatives containing a suflone group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).
Bayer Pharma Aktiengesellschaft

Method and removable catheter visual light therapeutic system

A medical device assembly is provided for removable insertion into a catheter with a lumen. The medical device assembly comprises an electromagnetic radiation (emr) source for providing non-ultraviolet, therapeutic emr having an intensity sufficient to inactivate one or more infectious agents and/or to stimulate healthy cell growth causing a healing effect, and a removable emr conduction system at least partially insertable into and removable from the lumen of the catheter.

An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Aptamers that bind to and antagonize pd-1 and uses thereof in promoting t cell proliferation, treating cancer or infectious diseases such as hiv infection.. .
National Taiwan University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Novel compounds for the treatment of infectious diseases

Wherein r1, r2, r3, r4, r5 and r6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.. .

4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (i) or (ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i) or (ia)..
Bayer Intellectual Property Gmbh

Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Compounds of formula i: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where r1, r2, ra, rb, rc, rd, x, y, b, and ring c are as defined herein, and wherein the y—b moiety and the nh—c(═x)—nh moiety are in the trans configuration, are inhibitors of trka kinase and are useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma Inc.

Vaccine pharmaceutical composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as serratia, lelercia, rahnella, acidicaldus, acidiphilium, acidisphaera, acidocella, acidomonas, asaia, belnapia, craurococcus, gluconacetobacter, gluconobacter, kozakia, leahibacter, muricoccus, neoasaia, oleomonas, paracraurococcus, rhodopila, roseococcus, rubritepida, saccharibacter, stella, swaminathania, teichococcus, zavarzinia, pseudomonas, achromobacter, bacillus, methanoculleus, methanosarcina, clostridium, micrococcus, flavobacterium, pantoea, acetobacter, zymomonas, xanthomonas, and enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500..
Nitto Denko Corporation

Coronavirus

The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject..
The Pirbright Institute

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Devices, detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing, the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first electrolyte-insulator-semiconductor (eis) sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second eis sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Avails Medical, Inc.

Foxtail mosaic virus-based vectors for gene silencing and gene expression

The present invention provides plant virus vectors developed from the foxtail mosaic virus (fomv). The vectors include a nucleic acid sequence encoding an infectious foxtail mosaic virus (fomv) with a functional movement encoding sequence operably linked to one or more regulatory elements functional in a plant.
Iowa State University Research Foundation, Inc.

Immunostimulation by chemically modified rna

The present invention relates to an immunostimulating agent comprising at least one chemically modified rna. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent.
Curevac Ag

Antibody molecules to lag-3 and uses thereof

Antibody molecules that specifically bind to lag-3 are disclosed. The anti-lag-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders..
Immutep S.a.s.

Multispecific antigen binding proteins

Multimeric multispecific proteins formed from dimerization between ch1 and ck domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease..
Innate Pharma

Methods and systems for processing particles

Described herein are improved microfluidic devices and methods for processing cells that can improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..
University Of Maryland, Baltimore

Pegylated interferon-beta variant

The present invention provides a pegylated ifn-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the pegylated ifn-β variant as an effective ingredient. The pegylated ifn-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native ifn-β and non-pegylated ifn-β variants, and therefore can be used usefully against various diseases.
Abion Inc.

Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same

Provided herein are compositions and methods for preparing intraarticular formulations comprising biocompatible pharmaceutical agents and use thereof in the treatment of diseases, such as degenerative bone diseases, including osteoarthritis of the knee, hip, or other joints, and similar chronic or acute destructive arthropathies resulting from autoimmune disorders or infectious disease.. .
Board Of Regents, The University Of Texas Sytem

Use of prostacyclin antagonists for treating ocular surface nociception

The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort..
Jenivision Inc.

Polycomplex gel for treating diseases of intestinal/digestive tract

The invention relates to the chemical and pharmaceutical industry and consists of a rectal gel substance for treating diseases of the intestinal/digestive tract, including nonspecific ulcerative colitis, crohn's disease, fistulae, etc., and also complications during the course of treatment of said diseases. The invention provides an antimicrobial and antiprotozoal effect and has good penetration capabilities.
Obschestvo S Ogranichennoi Otvetstvennostyu "gelizovit"

Proximity tracing methods and systems

Infection control methods and systems associate proximity-detection devices with people in a population, such as people in a hospital. Each proximity-detection device detects proximity events with other people.

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Il-33 antagonists and uses thereof

The present invention provides interleukin-33 (il-33) antagonists comprising one or more il-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the il-33-binding domains can comprise an il-33-binding portion of an st2 protein and/or an extracellular portion of an il-1racp protein.

Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions

Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“il-15”) covalently or noncovalently bound to il-15 receptor alpha (“il-15rα”) to patients in order to enhance il-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing il-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficienices and lymphopenia.
United States Departmen Of Health And Human Services

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Agents for the treatment of retroviral infectious diseases

The invention relates to pyridine-3,5-bis-thiocyanates which are new active substances for the treatment and prevention of retroviral infections and secondary diseases thereof, in particular hiv infections and aids, from the group of deubiquitinase inhibitors. Administration of the compounds of the invention increases the immunogenicity of viral proteins and thus the antiviral response..
Immunologik Gmbh

Cultivation coffee tree by red ginseng powdered extract

A cultivation method of coffee tree by red ginseng powdered extract is provided, and particularly provided is a cultivation method of coffee tree through environment-friendly and rest (artificial dormant period) process using a red ginseng, and drink composition and food additive manufactured by the cultivation method of coffee tree by red ginseng, the method including: supplying red ginseng powdered extract aqueous solution to coffee seeds; and adjusting moisture of soil planted with coffee seeds. The cultivation method of coffee tree by red ginseng powdered extract has an advantageous effect in that coffee beans can be harvested having, as active ingredient, ginsenoside of high internal absorption rate capable of preventing occurrences of infectious diseases and pests by increasing immunity levels of coffee trees without using chemical fertilizers at all, and by enhancing germination percent of coffee seeds and coffee bean crops.

Psgl-1 modulators and uses thereof

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance.
Sanford-burnham Medical Research Institute

Anti-tigit antibodies

The present invention relates to anti-tigit antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme Corp.

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to tim-3 are disclosed. The anti-tim-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders..
Children's Medical Center Corporation

Multispecific nkp46 binding proteins

Multispecific proteins that bind and specifically redirect nk cells to lyse a target cell of interest are provided without non-specific activation of nk cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease..
Innate Pharma

Single chain antigen recognizing constructs (scarcs) stabilized by the introduction of novel disulfide bonds

The present invention relates to a single chain antigen recognizing construct (scarc), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous arc chains. The invention further discloses a method for the design of a novel structurally stabilized scarc, the method being based on the visual inspection of the crystal structure of the underlying scarc and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure.
Universitätsmedizin Der Johannes Gutenberg-universität Mainz

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Curevac Ag

Drug target and construct for japanese encephalitis virus infection

A group of mosquito-borne flaviviruses that cause fatal encephalitis in humans is among the most important of all emerging human pathogens of global significance. This group includes japanese encephalitis virus (jev), west nile virus, st.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

Rapid detection of infectious agents

The invention generally relates to a method for detecting a target nucleic acid in a sample. This invention is useful for detecting bacterial or viral agents in a sample, and is able to detect nucleic acids from a broad variety of, e.g., bacteria, rather than only one or a few different bacteria at a time..
University Of Florida Research Foundation, Inc.

Perforin 2 defense against invasive and multidrug resistant pathogens

Perforin-2 (p2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, mycobacteria smegmatis, m. Avium, salmonellae, mrsa (drug resistant stapholococci), e.
University Of Miami

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to tim-3 are disclosed. The anti-tim-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders..
Children's Medical Center Corporation

Vacuum assisted percutaneous applicance

A luminal access device is provided that includes a luminal graft attached to a patient lumen. A percutaneous access device (pad) is coupled to the luminal graft and adapted to stabilize a conduit in fluid communication with the luminal graft and an external medical device.
Viaderm, Llc

New medical agents and uses thereof

The invention provides a novel compounds derived from cd154, but without the intracellular domain. Notably, the invention provides tmz-cd154 and a method to treat diseases in which the novel molecule tmz-cd154 is used.
Lokon Pharma Ab

Composition for preventing or treating staphylococcus aureus infection

A composition containing wall teichoic acid-attached peptidoglycan (wta-pgn) as an active ingredient, a method for preventing or treating staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble wta-pgn which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to t cell activation at the early stage of infection..
Pusan National University Industry-university Cooperation Foundation

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj26 (kccm11464p) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by salmonella by using the bacteriophage Φcj26 (kccm11464p) or the composition..
Cj Cheiljedang Corporation

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj24 (kccm11462p) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic e.
Cj Cheiljedang Corporation

Amide compounds, methods for preparation, and use thereof as agents for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases

The present invention relates to medicine and includes a method for preventing and treating diseases caused by rna- and dna-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula i or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by rna- and dna-containing viruses, said compositions comprising an effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof.
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"

Cd40 ligand fusion protein vaccine

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein.
Microvax, Llc

Composition and reducing zoonotic infectious diseases

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject.
Us Biologic, Inc.

Mediated access to resources

Today's user is facing an ever increasing number of cyber threats from infectious software to scam artist phishing for their passwords and other personal information. Accordingly, a technique is provided to mediate a user's access to electronic resources, which can include malware and sites that trick the user into giving their password.
Mimecast North America, Inc.

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited

Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine.
Universitaetsklinikum Heidelberg

Live attenuated chimeric porcine circovirus vaccine

The present invention provides a novel chimeric porcine circovirus infectious dna clone and live attenuated chimeric virus with the pcv2, preferably of subtype pcv2b, capsid gene integrated into a non-pathogenic pcv1 virus genome. In a particular embodiment, the pcv2 capids gene is of subtype pcv2b, the predominant subtype circulating in pigs worldwide.
Virginia Tech Intellectual Properties, Inc.

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.

Color-coded accessories indicating a medical diagnosis of a patient and enhancing patient safety

The present invention provides color-coded accessories such as wristbands, bibs, and other patient wearables, color-coded pillows and pillow cases, and a universal chart wherein the color code is associated with a specific medical diagnosis. These accessories alert healthcare providers to the medical diagnosis of the patient and enhance patient safety by reducing medical errors during administration of treatments and medicines to the patients.

Systems and methods for detecting infectious diseases

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.

Differential diagnostic method and kit for infectious and parasitic diseases, using flow cytometry

The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analyzing the reactivity profile of igg1 to the biological agents.
Fundacao Oswaldo Cruz

Dnazyme-nanoparticle conjugates and methods of use thereof

The present invention relates to dnazymes (also known as deoxyribozymes, dna enzymes, catalytic dna, or dz), which are conjugated to nanoparticles (np) to facilitate the detection of nucleic acids. One aspect of the invention relates to compounds comprising dnazymes conjugated to nanoparticles (dz-np), such as metallic or gold nanoparticles, and methods for their synthesis.
The University Of Notre Dame

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“p2”) on pd-1 that is linked with a previously unidentified functional activity of pd-1 that is distinct from the interaction site involved with either the pd-l1 or pd-l2 ligands.
Mabquest Sa

Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in birt-hogg-dubé syndrome, chronic erosive oral lichen planus, early stage cutaneous t-cell lymphoma, treatment of autoimmune active anterior uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), pachyonychia congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose..
Druggability Technologies Ip Holdco Limited

Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

The present application generally relates to the discovery that glycogen synthase kinase 3 (gsk-3) is an upstream signalling molecule that controls pd-1 transcription and tbet expression by immune cells and in particular t-cells. Based on this discovery, and in view of the known immunosuppressive effect of pd-1 on immunity and the promoting effect of tbet on t cell immunity, the present invention relates to the use of gsk-3 inhibitors to promote immunity, including cytotoxic t cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting pd-1 expression and/or blockade or tbet up-regulation is therapeutically desirable such as cancer and infectious conditions.

Intraocular delivery devices and methods therefor

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall.
Ocuject, Llc

Sterile site apparatus, system, and using the same

Apparatus, system, and methods are provided for reducing infectious agents at a sterile site by preventing infectious agents from coming into contact with the sterile site. A barrier is produced for infectious agents that may come in proximity or otherwise communicate with the site.
Armour Technologies, Inc.

Chemical gel to dissolve metal and hazardous medical sharps

This dissolvent is an inorganic compound of silica gel that is stabile and lasts for decades. Pleasant gold color, no evident odor or vapor, and it will not spill, or degrade over the decades, while awaiting use.

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Protein kinase inhibitors

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated..
Pharmascience Inc.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, y, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Replication-competent vesicular stomatitis viruses

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided..
Mayo Foundation For Medical Education And Research

Time zero classification of messages

Detecting infectious messages comprises performing an individual characteristic analysis of a message to determine whether the message is suspicious, determining whether a similar message has been noted previously in the event that the message is determined to be suspicious, classifying the message according to its individual characteristics and its similarity to the noted message in the event that a similar message has been noted previously.. .
Dell Software Inc.

Improved nanoparticle type oligonucleotide structure having high efficiency and preparing same

The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same. The oligonucleotide structure is improved into a homogenous material, thereby solving the problem in material verification due to polydispersion characteristics occurring when a hydrophilic material linked to the oligonucleotide is a synthetic polymer; the oligonucleotide structure is easy to synthesize compared with the existing process; and the size of a double-stranded oligo rna structure can be accurately adjusted through the control of the repetition number of a hydrophilic material block, and thus, the gene expression regulation function of the oligonucleotide does not deteriorate through the synthesis of the optimized oligonucleotide structure, and the oligonucleotide can be delivered into cells at even a relatively low-concentration dosage.
Bioneer Corporation

Targeted conjugates and particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided.
Tarveda Therapeutics, Inc.

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..
Bovicor Pharmatech Inc.



Infectious topics:
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Autoimmune
  • Autoimmune Disease
  • Immune Disease
  • Modulation
  • Nucleotide
  • Killer Cells
  • Natural Killer Cell
  • Stem Cells
  • Amplification
  • Dna Sequence
  • Single Nucleotide Polymorphism
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Infectious for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Infectious with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.1081

    file did exist - 12961

    2 - 1 - 254